Specialty pharmacy

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)

Retrieved on: 
Monday, April 8, 2024
Immune system, PNH, Specialty pharmacy, Patient, Ravulizumab, FDA, Eculizumab, Paroxysmal nocturnal hemoglobinuria, EVH, Blood, Alexion Pharmaceuticals

LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor.

Key Points: 
  • LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for Voydeya® (Danicopan) as a first class oral, Factor D inhibitor.
  • It is FDA-approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in combination with C5 inhibitor, Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients that experience clinically significant extravascular hemolysis (EVH).1 Voydeya® is an oral, Factor D inhibitor that acts in the alternative complement pathway of the immune system, providing control of red blood cell destruction within and outside the blood vessels.
  • “Onco360 appreciates the opportunity to partner further with the team at Alexion and become the sole national specialty pharmacy provider for Voydeya®”, said Benito Fernandez, Chief Commercial Officer.
  • “We are proud to add this first in class oral Factor D inhibitor treatment option for PNH patients.”

Registration Opens for the National Association of Specialty Pharmacy 2024 Annual Meeting & Expo

Retrieved on: 
Tuesday, March 12, 2024
Convention center, Pharmacist, Annual, Organ transplantation, Rheumatoid arthritis, CE, Woman, Multiple sclerosis, Haemophilia, Pharmacy, Patient, Cancer, Abstract, Love, Specialty pharmacy, National Association, CSP, Cell, Data management, Nursing, Education, NASP, Consultant, Cystic fibrosis, Accreditation, Hospital

Washington, DC, March 12, 2024 (GLOBE NEWSWIRE) -- Today, the National Association of Specialty Pharmacy (NASP), the only industry association in the U.S. whose membership includes all specialty pharmacy stakeholders, opened registration for the NASP 2024 Annual Meeting & Expo, to be held October 6 - 9, 2024, at the Gaylord Opryland Resort & Convention Center in Nashville, TN.

Key Points: 
  • Washington, DC, March 12, 2024 (GLOBE NEWSWIRE) -- Today, the National Association of Specialty Pharmacy (NASP), the only industry association in the U.S. whose membership includes all specialty pharmacy stakeholders, opened registration for the NASP 2024 Annual Meeting & Expo, to be held October 6 - 9, 2024, at the Gaylord Opryland Resort & Convention Center in Nashville, TN.
  • “The NASP 2024 Annual Meeting & Expo offers everything that attendees have come to love and expect, including top-of-class educational content and networking events.
  • Workshops include Accreditation, Cell & Gene Therapy, Certified Specialty Pharmacist (CSP) Exam Prep Course, Hospital/Health System Specialty Pharmacy, Specialty Pharmacy Law, and Technology.
  • The Annual Meeting & Expo also features a showcase for specialty pharmacy clinical research with its abstract and poster program.

Congress’ Current Failure to Enact PBM Reforms in Medicare and Medicaid is a Wasted Opportunity; Such Action Remains Must-Pass Legislation in 118th Congress

Retrieved on: 
Monday, March 4, 2024
Pharmacy, National Association, Food industry, American Pharmacists Association, Specialty pharmacy, FMI, Congress, PBM, Medicaid, National Alliance, Pharmaceutical industry

“In the current must-pass legislation, Congress’ failure to enact PBM reforms for Americans in Medicare and Medicaid and for their pharmacies is nothing short of a wasted opportunity – at a moment when time cannot be wasted.

Key Points: 
  • “In the current must-pass legislation, Congress’ failure to enact PBM reforms for Americans in Medicare and Medicaid and for their pharmacies is nothing short of a wasted opportunity – at a moment when time cannot be wasted.
  • “Congress demonstrated broad and strong bipartisan support for sound PBM reforms in Medicare and Medicaid.
  • “It is imperative that Congress enact these reforms soon in the 118th Congress.
  • We stand ready to support that effort because if ever there were must-pass legislation, PBM reforms in Medicare and Medicaid are it.”

Jessica Ringena Named President of Amber Specialty Pharmacy

Retrieved on: 
Monday, February 19, 2024
Finance, Other Retail, Supermarket, Professional Services, Other Health, Health, Pharmaceutical, General Health, Retail, LLP, Pharmacy, Specialty pharmacy, National Association, Multimedia, RSM US, Patient, Hospital

Amber Specialty Pharmacy announces the appointment of Jessica Ringena as its newest president.

Key Points: 
  • Amber Specialty Pharmacy announces the appointment of Jessica Ringena as its newest president.
  • View the full release here: https://www.businesswire.com/news/home/20240219314062/en/
    Jessica Ringena, president of Amber Specialty Pharmacy (Photo: Business Wire)
    Known for her strategic leadership in health care, technology, finance and innovation, Ringena will lead the specialty pharmacy in its mission to deliver personalized care to patients who experience chronic and complex conditions.
  • Amber Specialty Pharmacy offers a comprehensive care model that includes medication management, therapy-specific counseling, and 24/7 clinical support and was recognized as Specialty Pharmacy of the Year in 2020 by the National Association of Specialty Pharmacy.
  • In 2022, Ringena was named president of Vivid Clear Rx, Hy-Vee’s newly established pharmacy benefit manager.

BENECARD CENTRAL FILL MAIL ORDER PHARMACY AWARDED PRESTIGIOUS URAC ACCREDITATION IN SPECIALTY PHARMACY

Retrieved on: 
Friday, February 9, 2024
Risk management, URAC, Education, Specialty pharmacy, Accreditation, Pharmacy, Health, Quality of life, Conditional sentence, Doctor of Pharmacy, Certification, Nursing

BONITA SPRINGS, Fla., Feb. 9, 2024 /PRNewswire/ -- Benecard Central Fill, LLC, the mail order pharmacy affiliated with BeneCard PBF, a prescription benefit manager focused on providing superior services to members based on clinical and technological innovations, has been awarded the URAC (Utilization Review Accreditation Commission) Specialty Pharmacy Accreditation.

Key Points: 
  • BONITA SPRINGS, Fla., Feb. 9, 2024 /PRNewswire/ -- Benecard Central Fill, LLC, the mail order pharmacy affiliated with BeneCard PBF, a prescription benefit manager focused on providing superior services to members based on clinical and technological innovations, has been awarded the URAC (Utilization Review Accreditation Commission) Specialty Pharmacy Accreditation.
  • "As has been true since its inception, Benecard Central Fill will continue to concentrate its efforts on behalf of its clients and members.
  • Now, having received URAC's Specialty Pharmacy accreditation, BeneCard is recognized for our stringent protocols, and supremely high standards of patient care, ultimately delivering overall better health care for all members," said Michael Perry, President BeneCard PBF and Benecard Central Fill.
  • By achieving URAC accreditation, Benecard demonstrates excellence in quality care delivery and their long-term commitment to ensuring patient safety and improving outcomes."

DirectRx Pharmacy Earns URAC Accreditation in Specialty Pharmacy

Retrieved on: 
Wednesday, January 17, 2024
URAC, Patient, Specialty pharmacy, Accreditation, ACHC, Pharmacy, Investment, Risk management, Benchmarking, Patient safety, Education

TROY, Mich., Jan. 17, 2024 (GLOBE NEWSWIRE) -- DirectRx specialty pharmacy is proud to announce that it has once again earned URAC accreditation for Specialty Pharmacy.

Key Points: 
  • TROY, Mich., Jan. 17, 2024 (GLOBE NEWSWIRE) -- DirectRx specialty pharmacy is proud to announce that it has once again earned URAC accreditation for Specialty Pharmacy.
  • DirectRx Pharmacy is an independent Specialty Pharmacy that holds dual accreditation from both URAC and ACHC and dispenses medications that target a specific population with chronic and sometimes life-threatening diseases.
  • URAC congratulates DirectRx on their achievement of Specialty Pharmacy Accreditation.
  • DirectRx, an independent specialty pharmacy with dual accreditation from both ACHC and URAC, provides patients with unparalleled, personalized pharmaceutical care.

3rd Annual 'Pharmacy 50' Awards Recognizing the Most Influential Leaders in Pharmacy Event on January 17th, 2024

Retrieved on: 
Wednesday, January 10, 2024
IPC, Cardinal, Specialty pharmacy, Cardinal Health, Pharmacy, PPN, Entertainment

BROWNSVILLE, Pa., Jan. 10, 2024 /PRNewswire/ -- The Pharmacy Podcast Network (PPN) is excited to announce the highly anticipated 3rd Annual 'Pharmacy 50' Awards, celebrating the outstanding achievements and contributions of the 50 most influential leaders in the field of pharmacy.

Key Points: 
  • BROWNSVILLE, Pa., Jan. 10, 2024 /PRNewswire/ -- The Pharmacy Podcast Network (PPN) is excited to announce the highly anticipated 3rd Annual 'Pharmacy 50' Awards, celebrating the outstanding achievements and contributions of the 50 most influential leaders in the field of pharmacy.
  • The 'Pharmacy 50' Awards honor those who have made remarkable strides within the pharmacy profession.
  • These categories include Independent Pharmacy, Specialty Pharmacy, Long-term Care Pharmacy, Advocacy, Academia, and nine others, showcasing the diverse and impactful roles within the industry.
  • For more information about the 'Pharmacy 50' Awards and the Pharmacy Podcast Network, please visit Pharmacy50.us

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

Retrieved on: 
Wednesday, January 3, 2024
Walgreens, FDA, Specialty pharmacy, Patient, Dermatology, Therapy, Skin, Molluscum contagiosum, Fungal infection

WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it is growing its distribution network by entering into an agreement with Walgreen Co. (“Walgreens”) to distribute YCANTH™ through its specialty pharmacy.

Key Points: 
  • WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it is growing its distribution network by entering into an agreement with Walgreen Co. (“Walgreens”) to distribute YCANTH™ through its specialty pharmacy.
  • Walgreens joins Verrica’s existing specialty pharmacy, Nufactor, who continues to be instrumental in helping the Company build awareness of YCANTH therapy among high volume dermatology and pediatric medical practices.
  • “Walgreens and Verrica mutually recognize the need to address this significant unmet medical need in dermatology, and we look forward to working together to provide greater access to YCANTH for patients in need.
  • We will also continue to work closely with Nufactor, our other Specialty Pharmacy, who continues to be an extraordinary partner.”

FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Wednesday, December 20, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Patient, Specialty pharmacy, Bone marrow failure, Immune system, Pharmacy, Thrombosis, Blood, Hemolysis, PNH, RBC, Novartis, Mutation, Medication, Paroxysmal nocturnal hemoglobinuria

“Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.

Key Points: 
  • “Onco360 is grateful for the opportunity to partner with the team at Novartis and become a specialty pharmacy provider for Fabhalta®,” said Benito Fernandez, Chief Commercial Officer.
  • Every year, roughly 500 patients in the U.S. are diagnosed with PNH.3 An estimated 10-16 cases per million patients around the world have PNH.
  • Most patients are diagnosed with PNH in their 30s and 40s.
  • Please see the full Prescribing Information for Fabhalta, including Boxed WARNING and Medication Guide.®

AIS Healthcare Recognized by Accreditation Commission for Health Care

Retrieved on: 
Tuesday, December 12, 2023
General Health, Pharmaceutical, Health, Accreditation, Specialty pharmacy, Infusion, Commission, Patient safety, Patient, ACHC, TDD, Nursing

AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to announce that it is has been awarded accreditations for Specialty Pharmacy, Infusion Pharmacy, and Infusion Nursing by the Accreditation Commission for Health Care (ACHC), an internationally recognized accrediting body, further setting it apart from other infusion services providers.

Key Points: 
  • AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to announce that it is has been awarded accreditations for Specialty Pharmacy, Infusion Pharmacy, and Infusion Nursing by the Accreditation Commission for Health Care (ACHC), an internationally recognized accrediting body, further setting it apart from other infusion services providers.
  • Formed in 1986, the Accreditation Commission for Health Care grants accreditation for providers in the home care and home infusion therapy industries.
  • Accreditation also helps providers like AIS Healthcare to demonstrate their ability to meet official regulatory requirements and standards, resulting in a higher level of performance and a greater focus on patient care.
  • Thank you to ACHC for this important recognition and to the entire team at AIS Healthcare for their dedication to the patients we serve,” said Simon Castellanos, AIS Healthcare CEO.